135 related articles for article (PubMed ID: 17692108)
1. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Nihoyannopoulos P; Kemp M; Hooper J; Rajkumar C
Clin Endocrinol (Oxf); 2008 Jan; 68(1):59-65. PubMed ID: 17692108
[TBL] [Abstract][Full Text] [Related]
2. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer.
Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Rajkumar C
J Androl; 2009; 30(4):410-5. PubMed ID: 19168445
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
4. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
5. [Endocrine therapy for prostate cancer in the future].
Usami M
Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
[TBL] [Abstract][Full Text] [Related]
6. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
7. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
[TBL] [Abstract][Full Text] [Related]
8. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
10. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
[TBL] [Abstract][Full Text] [Related]
11. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
12. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
[TBL] [Abstract][Full Text] [Related]
13. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
15. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
Perachino M; Cavalli V; Bravi F
BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
[TBL] [Abstract][Full Text] [Related]
16. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2011 Jun; 107(12):1923-9. PubMed ID: 20950306
[TBL] [Abstract][Full Text] [Related]
17. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
18. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
[TBL] [Abstract][Full Text] [Related]
19. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
[TBL] [Abstract][Full Text] [Related]
20. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
Morote J; Planas J; Salvador C; Raventós CX; Catalán R; Reventós J
BJU Int; 2009 Feb; 103(3):332-5; discussion 335. PubMed ID: 19007366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]